For over three decades, a mainstay and goal of clinical oncology has been the development
of therapies promoting the effective elimination of cancer cells by apoptosis. This …

Cell suicide pathways, termed regulated cell death (RCD), play a critical role in organismal
development, homeostasis, and pathogenesis. Here, we provide an overview of key RCD …

Functional precision medicine is a strategy whereby live tumor cells from affected individuals
are directly perturbed with drugs to provide immediately translatable, personalized …

With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …

The loss of vital cells within healthy tissues contributes to the development, progression and
treatment outcomes of many human disorders, including neurological and infectious …

Older patients with acute myeloid leukemia (AML) respond poorly to standard induction
therapy. B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells …

Combining venetoclax, a selective BCL2 inhibitor, with low-dose navitoclax, a BCL-XL/BCL2
inhibitor, may allow targeting of both BCL2 and BCL-XL without dose-limiting …

Opinion statement Relapse is still a common scenario in acute myeloid leukemia (AML)
treatment and occurs in 40–50% of younger and the great majority of elderly patients. The …

Despite high initial response rates, acute myeloid leukemia (AML) treated with the BCL-2–
selective inhibitor venetoclax (VEN) alone or in combinations commonly acquires …

Impaired apoptosis plays a central role in cancer development and limits the efficacy of
conventional cytotoxic therapies. Deepening understanding of how opposing factions of the …